{"entity":{"id":"juri-biosciences","kind":"company","name":"Juri Biosciences","aka":[],"tldr":"Juri Biosciences develops JUR-003, an antibody that directs the immune system's T cells to prostate cancer cells carrying a protein called KLK2. It is being tested for the first time in people with metastatic prostate cancer.","summary":"Juri Biosciences, Inc. is a single-asset portfolio company formed by TCG Labs Soleil, the venture-biotech organisation run in collaboration with The Column Group. In May 2025 Juri took an exclusive worldwide licence from EpimAb Biotherapeutics to a KLK2 x CD3 T-cell engager for metastatic prostate cancer, with EpimAb eligible for up to $210 million in upfront and milestone payments plus royalties. JUR-003, the lead of Juri's KLK2-directed T-cell engagers, is a bispecific antibody designed for subcutaneous dosing. Its first registered cancer trial, NCT07824349, a phase 1a/1b dose-escalation and expansion study of intravenous JUR-003 in metastatic castration-resistant, hormone-sensitive and oligometastatic prostate cancer, was posted on ClinicalTrials.gov in September 2026.","asOf":"2026-10-29","links":[{"label":"TCG Labs Soleil: Juri and EpimAb KLK2 licence, May 2025","url":"https://www.tcglsoleil.com/news/juri-biosciences-a-tcg-labs-soleil-portfolio-company-and-epimab-biotherapeutics-enter-into-a-worldwide-licensing-agreement-for-klk2-directed-t-cell-engager-in-metastatic-prostate-cancer/"},{"label":"TCG Labs Soleil: three programmes enter first-in-human trials, October 2026","url":"https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/"},{"label":"ClinicalTrials.gov: phase 1a/1b trial of JUR-003 in metastatic prostate cancer (NCT07824349)","url":"https://clinicaltrials.gov/study/NCT07824349"}],"tags":[],"related":[],"cancers":["prostate","prostate-mcrpc","prostate-mhspc"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["klk2","cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Juri has no website of its own that could be found; facts come from TCG Labs Soleil press releases dated 27 May 2025 and 28 October 2026 and from the registry record, read on 29 October 2026.","Headquarters city is taken from the San Francisco dateline of the TCG Labs Soleil releases; Juri's own address is not published.","The October 2026 release describes JUR-003 as designed for subcutaneous administration, while the registry record says it will be given intravenously in this trial.","Founding year and financing amounts for Juri itself are not stated."],"hq":"San Francisco, CA","country":"US","companyType":"biotech","stage":"startup","investors":[],"funding":[]},"route":"/companies/juri-biosciences/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/"}]}}